SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough therapies against otherwise undruggable disease-causing targets, today announced the appointment of Mark Dizon, J.D., to the position of general counsel.
“Mark has extensive experience building and scaling legal departments to support companies as they progress from discovery through commercialization, and this experience will be invaluable as we continue to grow the company and prepare to enter the clinic with our activated KRASG12C inhibitor program,” said Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO. “In addition to scaling our legal and regulatory capabilities, Mark will be involved in business development and portfolio strategies to support the continued advancement of our rich pipeline of groundbreaking programs.”
Prior to joining Frontier, Mr. Dizon was the assistant general counsel and chief compliance officer at BeiGene, Ltd., and was responsible for global compliance, healthcare (R&D and commercial) law, data privacy, employment law, enterprise risk management, and litigation. While at BeiGene, he supported 30+ clinical studies globally, resulting in more than a dozen regulatory approvals for BeiGene products, including tislelizumab (anti-PD-1 monoclonal antibody, pamiparib (PARP inhibitor), and zanubrutinib (BTK inhibitor). In addition, he collaborated closely with...
AIDS Healthcare Foundation will pay $1.44 million to resolve allegations that it violated federal law by submitting false or invalid codes to inflate payments from the Medicare Advantage program. ...